Axovant Sciences Ltd. (AXON) Reaches $2.09 Low on Jan, 14; Dolan Co (DM) Sentiment Is 1.07

January 14, 2018 - By Louis Casey

Dominion Energy Midstream Partners, LP owns liquefied natural gas import, storage, regasification, and transportation assets. The company has market cap of $3.15 billion. It owns and operates LNG facility located on the Chesapeake Bay in Lusby, Maryland; and has approximately 136 miles of natural gas pipeline that connects its LNG facility to interstate natural gas pipelines. It has a 22.72 P/E ratio. The firm also operates an interstate pipeline in South Carolina and southeastern Georgia comprising natural gas system consisting of approximately 1,500 miles of transmission pipeline and 5 compressor stations with approximately 38,700 installed compressor horsepower.

The stock of Axovant Sciences Ltd. (NASDAQ:AXON) reached all time low today, Jan, 14 and still has $1.96 target or 6.00% below today’s $2.09 share price. This indicates more downside for the $225.11 million company. This technical setup was reported by Barchart.com. If the $1.96 PT is reached, the company will be worth $13.51 million less. The stock decreased 7.93% or $0.18 during the last trading session, reaching $2.09. About 4.64M shares traded or 196.02% up from the average. Axovant Sciences Ltd. (NASDAQ:AXON) has risen 97.46% since January 14, 2017 and is uptrending. It has outperformed by 80.76% the S&P500.

Chickasaw Capital Management Llc holds 3.69% of its portfolio in Dominion Energy Midstream Partners, LP for 5.38 million shares. Spirit Of America Management Corp Ny owns 794,981 shares or 2.69% of their US portfolio. Moreover, Yorkville Capital Management Llc has 2.62% invested in the company for 70,710 shares. The Wisconsin-based A. D. Beadell Investment Counsel Inc. has invested 2.52% in the stock. Nbw Capital Llc, a Massachusetts-based fund reported 269,022 shares.

Analysts await Dominion Energy Midstream Partners, LP (NYSE:DM) to report earnings on February, 7. They expect $0.38 EPS, 0.00% or $0.00 from last year’s $0.38 per share. DM’s profit will be $37.80 million for 20.82 P/E if the $0.38 EPS becomes a reality. After $0.33 actual EPS reported by Dominion Energy Midstream Partners, LP for the previous quarter, Wall Street now forecasts 15.15% EPS growth.

The stock decreased 1.71% or $0.55 during the last trading session, reaching $31.65. About 247,946 shares traded or 42.00% up from the average. Dominion Energy Midstream Partners, LP (DM) has risen 2.59% since January 14, 2017 and is uptrending. It has underperformed by 14.11% the S&P500.

Ratings analysis reveals 67% of Dominion Midstream’s analysts are positive. Out of 3 Wall Street analysts rating Dominion Midstream, 2 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $29.0 while the high is $30.0. The stock’s average target of $29.50 is -6.79% below today’s ($31.65) share price. DM was included in 3 notes of analysts from August 18, 2016. Mizuho initiated Dominion Energy Midstream Partners, LP (NYSE:DM) on Friday, September 30 with “Buy” rating. The firm has “Equal-Weight” rating given on Thursday, August 18 by Morgan Stanley. The rating was upgraded by Stifel Nicolaus to “Buy” on Wednesday, September 14.

Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the United States and Europe. The company has market cap of $225.11 million. The Company’s lead product candidate, intepirdine, a selective 5-HT6 receptor antagonist, which is in Phase III clinical trial for the treatment of AlzheimerÂ’s disease; in Phase IIb clinical trial for treating dementia with Lewy bodies ; and in Phase II clinical trial for treating cait and balance in Alzheimer's disease, DLB, and Parkinson's disease dementia. It currently has negative earnings. The firm is also developing nelotanserin, a selective 5-HT2A receptor inverse agonist, which is in Phase II clinical trial for the treatment of visual hallucinations in patients with Lewy body dementia (LBD) and REM behavior disorder in patients with LBD.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>